Beacon Investment Advisory Services Inc. Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Beacon Investment Advisory Services Inc. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 80,232 shares of the biopharmaceutical company’s stock after acquiring an additional 3,637 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Gilead Sciences were worth $7,411,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bellevue Group AG boosted its position in Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after acquiring an additional 7,093 shares in the last quarter. Quantinno Capital Management LP grew its position in shares of Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares in the last quarter. IRON Financial LLC purchased a new stake in Gilead Sciences during the third quarter valued at approximately $830,000. Finally, Capital Investment Advisors LLC boosted its stake in Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after acquiring an additional 9,791 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.1 %

Shares of GILD opened at $93.04 on Thursday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The firm has a market capitalization of $115.95 billion, a P/E ratio of 1,033.78, a P/E/G ratio of 1.31 and a beta of 0.18. The firm has a 50-day moving average price of $91.63 and a 200 day moving average price of $84.63. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business earned $2.29 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GILD shares. Wells Fargo & Company increased their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Truist Financial lifted their price target on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Finally, Barclays lifted their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.